Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Showcase Companies

Stockhouse is proud to showcase a portfolio of companies that we are watching closely. Learn more about these companies as part of your own investment research. Consider using the tools below to be first in line for important news and updates. view all showcase companies

NurExone Biologic Inc. V.NRX

NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following spinal cord injury (SCI) using Exosomes (membrane-bound extracellular vesicles). This technology, subject to conducting clinical trials and receiving Food and Drug Administration (the FDA) approval, can be used in various conditions such as SCI, Brain Trauma Injury (BTI), and potentially other brain and neurological indications.

Latest News

NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of...


NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on...


NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides...


Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise


In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale...


NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US...


NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel


NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit


NurExone's Intellectual Property Portfolio Expands


NurExone Launches Licensing Efforts for ExoTherapy Platform


Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant


Top 4 Spinal Injury Stocks for 2024 (NRX.V, NVRO, SYK, BSX)


NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar...


NurExone Biologic closes private placement of nearly C$2M


NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2...